<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;table id="schedule" class="data" border="0" cellspacing="0" summary="This table shows the date, time, and location of the meeting" cellpadding="2" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;th id="a2" bgcolor="#cccccc" valign="top" width="35%" align="left" style="height: 19px"&gt;Date&lt;/th&gt;&lt;th id="a3" bgcolor="#cccccc" valign="top" width="30%" align="left" style="height: 19px"&gt;Time&lt;/th&gt;&lt;th id="a4" bgcolor="#cccccc" valign="top" width="45%" align="left" style="height: 19px"&gt;Location&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="35%" headers="a2" style="height: 64px"&gt;&lt;!-- InstanceBeginEditable name="col2" --&gt;November 8,&amp;nbsp;2010&lt;br /&gt;November 9, 2010 &lt;!-- InstanceEndEditable --&gt;&lt;/td&gt;&lt;td valign="top" width="30%" headers="a3" style="height: 64px"&gt;&lt;!-- InstanceBeginEditable name="col3" --&gt;8:00 a.m. - 5:00 p.m.&lt;br /&gt;8:00 a.m. - 2:00 p.m.&lt;!-- InstanceEndEditable --&gt;&lt;/td&gt;&lt;td valign="top" width="45%" headers="a4" style="height: 65px"&gt;&lt;!-- InstanceBeginEditable name="col4" --&gt;FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31, Conference Center, Great Room,&amp;nbsp;Silver Spring, M.D. 20993&lt;!-- InstanceEndEditable --&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;h2 class="BlueBar"&gt;&lt;strong&gt;Agenda&lt;/strong&gt;&lt;/h2&gt;&lt;p&gt;&lt;!-- InstanceBeginEditable name="agenda" --&gt;On&amp;nbsp;November 8 and 9,&amp;nbsp;2010, the Committee will&amp;nbsp; hear and discuss developments in FDA's ongoing communications programs, such as FDA's Strategic Plan for Risk Communication, FDA's Transparency Initiative, foodborne outbreaks, related recall communications, and the challenges of effectively communicating with patients and caregivers about appropriate use of medical devices when a patient is prescribed a medical device for home use.&amp;nbsp;For more specific agenda information, please visit the following website and scroll down to the appropriate advisory committee link (&lt;em&gt;http://www.fda.gov/AdvisoryCommittees/default.htm&lt;/em&gt;), or call FDA Advisory Committee Information Line as listed in the Contact Person section of the notice. FDA intends to make agenda information available no later than 15 days before the meeting.&lt;/p&gt;&lt;h2 class="BlueBar"&gt;Procedure&amp;nbsp;&lt;/h2&gt;&lt;p&gt;Visitors to the White Oak Campus must have a valid driver's license or other picture ID, and must enter through Building 1. Please note visitors can park in the South-west garage near Building 31 or the North-west parking lot near Building 22 (for a campus map, see &lt;a href="http://www.fda.gov/downloads/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/UCM194893.pdf"&gt;http://www.fda.gov/downloads/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/UCM194893.pdf&lt;/a&gt;)&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;h2 class="BlueBar"&gt;&amp;nbsp;&lt;a href="[!--$ssLink(&amp;quot;ucm197164.htm&amp;quot;)--]"&gt;Other Meeting Materials&lt;/a&gt;&lt;/h2&gt;&lt;div class="noindent" style="margin-left: 2em"&gt;&lt;h2 class="BlueBar"&gt;Public Participation Information&amp;nbsp;&lt;/h2&gt;&lt;p&gt;&lt;!-- InstanceBeginEditable name="pubpart" --&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&amp;nbsp;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Written submissions may be made to the contact person on or before October 29, 2010.&amp;nbsp;&amp;nbsp;&lt;/li&gt;&lt;li&gt;Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. on November 8th and 10:30 to 11:30 a.m. on November 9th.&amp;nbsp;Those desiring to make formal oral presentations should notify Lee Zwanziger and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentations on or before October 21,&amp;nbsp;2010.&amp;nbsp;&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by October 22, 2010.&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;&lt;!-- InstanceEndEditable --&gt;&lt;/p&gt;&lt;h2 class="BlueBar"&gt;&lt;strong&gt;Contact Information&lt;/strong&gt;&lt;/h2&gt;&lt;p&gt;&lt;!-- InstanceBeginEditable name="contact" --&gt;&lt;/p&gt;&lt;ul class="listspace"&gt;&lt;li&gt;&lt;strong&gt;Lee L. Zwanziger, Designated Federal Official&lt;/strong&gt;&lt;br /&gt;10993 New Hampshire Avenue, Building 32, Room 3278&lt;br /&gt;Silver Spring, MD 20993&lt;/li&gt;&lt;li&gt;Phone 301-796-9151&lt;/li&gt;&lt;li&gt;FAX: 301-847-8611&lt;br /&gt;e-mail:&amp;nbsp; RCAC@fda.hhs.gov&lt;/li&gt;&lt;li&gt;&lt;strong&gt;FDA Advisory Committee Information Line&lt;/strong&gt;&lt;br /&gt;1-800-741-8138&lt;br /&gt;301-443-0572 in the Washington, DC, area&lt;br /&gt;code 8732112560&lt;br /&gt;Please call the Information Line for up-to-date information on this meeting.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting.&lt;/p&gt;&lt;p&gt;Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Lee L. Zwanziger at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at &amp;nbsp;http://www.fda.gov/AdvisoryCommittees/default.htm for procedures on public conduct during advisory committee meetings.&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).&lt;/p&gt;&lt;p align="center"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
